Hemlibra safely reduces bleeding episodes in people with hemophilia A without inhibitors, per a review study that confirmed ...

Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.

Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with hemophilia A or B with inhibitors.

A gene transfer approach to treating the bleeding disorder hemophilia B remains safe and effective long-term, as scientists from St. Jude Children's Research Hospital and University College London ...

Discover how hemophilia A affects blood clotting, its genetic patterns, warning signs, advanced treatment options, and lifestyle modifications ...

Often misunderstood and surrounded by myths, hemophilia is far more complex than most people think. From how it’s diagnosed ...

APRIL marks National Hemophilia Awareness Month in the Philippines. Hemophilia is a medical condition often unseen, yet it is a deeply challenging internal battle for those who live with it.

Hemophilia significantly impacts lives beyond bleeding episodes, causing absenteeism, pain, and disability. India, with the second-highest hemophilia ...

Hemophilia is a rare disorder in which the blood doesn't clot properly because it doesn't have enough blood-clotting proteins ...

Hemophilia is a genetic condition causing prolonged bleeding. Early diagnosis and treatment are crucial. Symptoms include frequent nosebleeds and bruising. Replacement therapy is a key treatment.

World Hemophilia Day 2025 highlights global awareness and calls for inclusive care for everyone affected by bleeding disorders.